1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Candidiasis - Pipeline Review, H1 2017

Candidiasis - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 147 pages

Candidiasis - Pipeline Review, H1 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Candidiasis - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Candidiasis - Overview 8
Candidiasis - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Candidiasis - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Candidiasis - Companies Involved in Therapeutics Development 27
Amplyx Pharmaceuticals Inc 27
Bakker Medical Srl 27
Biomar Microbial Technologies 28
Biosergen AS 28
Cidara Therapeutics Inc 29
CSA Biotechnologies LLC 29
Daewoong Pharmaceutical Co Ltd 30
Dermala Inc 30
General Biologicals Corp 31
Grupo Ferrer Internacional SA 31
Hsiri Therapeutics LLC 32
iCo Therapeutics Inc. 32
ImmunoClin Corp 33
Matinas BioPharma Holdings Inc 33
Nanomerics Ltd 34
NovaDigm Therapeutics Inc 34
Novartis AG 35
Onxeo SA 35
Scynexis Inc 36
Sealife PHARMA GMBH 36
Viamet Pharmaceuticals Inc 37
Visterra Inc 37
Wellstat Vaccines LLC 38
Candidiasis - Drug Profiles 39
(clotrimazole + diclofenac sodium) - Drug Profile 39
61894700 - Drug Profile 40
AC-17 - Drug Profile 41
amphotericin B - Drug Profile 42
amphotericin B - Drug Profile 44
amphotericin B - Drug Profile 48
Amphotericin B sodium - Drug Profile 49
Antibody to Target Ece1 for Candidiasis - Drug Profile 51
APX-001 - Drug Profile 52
APX-001A - Drug Profile 54
arasertaconazole - Drug Profile 55
B-4010 - Drug Profile 56
BL-5923 - Drug Profile 57
BSG-005 - Drug Profile 58
candidiasis vaccine - Drug Profile 59
CD-101 - Drug Profile 60
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 64
CSA-13 - Drug Profile 65
Drug for Candidiasis - Drug Profile 67
DWP-06081 - Drug Profile 68
Forazoline A - Drug Profile 69
iCo-010 - Drug Profile 70
interleukin-22 - Drug Profile 71
JSM-11 - Drug Profile 72
KSL-W - Drug Profile 73
miconazole nitrate - Drug Profile 74
Monoclonal Antibodies for Candidiasis - Drug Profile 76
Monoclonal Antibody for Candidiasis - Drug Profile 77
Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 78
mutanobactin A - Drug Profile 79
NDV-3 - Drug Profile 80
NDV-3A - Drug Profile 82
NP-339 - Drug Profile 84
obliquumol - Drug Profile 85
Occidiofungin - Drug Profile 86
P-113Du - Drug Profile 87
P-113Tri - Drug Profile 88
PAC-113 - Drug Profile 89
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 91
Prof-002 - Drug Profile 92
Recombinant Enzyme for Candidiasis - Drug Profile 93
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 94
SCY-078 - Drug Profile 95
SLP-0901 - Drug Profile 100
SLP-0904 - Drug Profile 101
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 102
Small Molecule for Fungal Infections - Drug Profile 103
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 104
Small Molecules for Candidiasis - Drug Profile 105
Small Molecules for Candidiasis - Drug Profile 106
Small Molecules for Candidiasis - Drug Profile 107
Small Molecules for Fungal Infections - Drug Profile 108
Small Molecules for Fungal Infections - Drug Profile 109
Small Molecules for Systemic Candidiasis - Drug Profile 110
Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 111
Synthetic Peptides for Candidiasis - Drug Profile 112
Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 113
TOL-463 - Drug Profile 114
Vaccine to Target Ece1 for Candidiasis - Drug Profile 115
Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 116
VIS-FNG - Drug Profile 117
VT-1129 - Drug Profile 118
VT-1161 - Drug Profile 120
Candidiasis - Dormant Projects 126
Candidiasis - Discontinued Products 129
Candidiasis - Product Development Milestones 130
Featured News and Press Releases 130
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

List of Tables
Number of Products under Development for Candidiasis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
Candidiasis - Pipeline by Bakker Medical Srl, H1 2017
Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2017
Candidiasis - Pipeline by Biosergen AS, H1 2017
Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2017
Candidiasis - Pipeline by CSA Biotechnologies LLC, H1 2017
Candidiasis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Candidiasis - Pipeline by Dermala Inc, H1 2017
Candidiasis - Pipeline by General Biologicals Corp, H1 2017
Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
Candidiasis - Pipeline by Hsiri Therapeutics LLC, H1 2017
Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2017
Candidiasis - Pipeline by ImmunoClin Corp, H1 2017
Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
Candidiasis - Pipeline by Nanomerics Ltd, H1 2017
Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2017
Candidiasis - Pipeline by Novartis AG, H1 2017
Candidiasis - Pipeline by Onxeo SA, H1 2017
Candidiasis - Pipeline by Scynexis Inc, H1 2017
Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2017
Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
Candidiasis - Pipeline by Visterra Inc, H1 2017
Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2017
Candidiasis - Dormant Projects, H1 2017
Candidiasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Candidiasis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Candidiasis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Candidiasis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Companies Mentioned
Amplyx Pharmaceuticals Inc
Bakker Medical Srl
Biomar Microbial Technologies
Biosergen AS
Cidara Therapeutics Inc
CSA Biotechnologies LLC
Daewoong Pharmaceutical Co Ltd
Dermala Inc
General Biologicals Corp
Grupo Ferrer Internacional SA
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
ImmunoClin Corp
Matinas BioPharma Holdings Inc
Nanomerics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Onxeo SA
Scynexis Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.